Should You Buy Teva Pharmaceutical Industries Ltd (TEVA) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Teva Pharmaceutical Industries Ltd (TEVA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive analyst sentiment and potential long-term catalysts, the recent financial performance, technical indicators, and lack of strong trading signals suggest waiting for a clearer entry point.
Technical Analysis
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 50.035, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 32.049, with support at 31.01 and resistance at 33.088.
Analyst Ratings and Price Target Trends
Analysts are bullish, with recent upgrades in price targets ranging from $31 to $40. Analysts highlight pipeline catalysts, R&D productivity, and margin expansion as key drivers for future growth.
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 33.210
Current: 33.210
